QGEN vs. REGN: Qiagen vs. Regeneron Pharmaceuticals Stock Comparison

November 11, 2026

How do Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but QGEN is classified in Life Sciences Tools & Services while REGN is classified in Biotechnology.

Company profile comparison for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Profile Item	QGEN	REGN
Name	Qiagen N.V.	Regeneron Pharmaceuticals, Inc.
Country/Region	Netherlands	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	10.39 billion USD	93.55 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 28, 1996	April 2, 1991
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

QGEN

REGN

GSPC

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
Total Return (1Y)	17.09%	40.87%
Total Return (3Y, Annualized)	10.44%	5.15%
Total Return (5Y, Annualized)	-0.72%	8.58%

Risk Profile

Drawdown History

QGEN

REGN

GSPC

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
Volatility (1Y, Annualized)	35.52%	34.08%
Beta (5Y)	0.56	0.10
Max Drawdown (5Y)	-41.97%	-59.69%
Avg. Volume (3M)	3.68M	772.95K

Risk-Adjusted Performance

Risk-Return Positioning

QGEN and REGN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
Sharpe Ratio (1Y)	0.36	1.07
Sortino Ratio (1Y)	0.60	1.70

Profitability

ROE (TTM)

Both Qiagen (QGEN) at 10.81% and Regeneron Pharmaceuticals (REGN) at 14.95% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.81%

Max: 109.18%
QGEN: 10.81%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Qiagen (QGEN) at 18.20% and Regeneron Pharmaceuticals (REGN) at 28.51% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.20%

QGEN: 18.20%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Qiagen (QGEN) at 27.75% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.75%

Max: 83.12%
QGEN: 27.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
ROE (TTM)	10.81%	14.95%
ROA (TTM)	5.68%	7.59%
Net Margin (TTM)	18.20%	28.51%
Operating Margin (TTM)	27.75%	40.46%
Gross Margin (TTM)	67.06%	46.73%

Growth

Revenue Growth

Both Qiagen (QGEN) at 5.65% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Qiagen (QGEN) at 409.76% clears its industry range for EPS growth, a much stronger earnings trajectory than Regeneron Pharmaceuticals (REGN) at 8.19%, which is closer to a typical peer reading.

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
Revenue Growth (YoY)	5.65%	0.99%
Revenue Growth (3Y CAGR)	-0.81%	5.62%
EPS Growth (YoY)	409.76%	8.19%
EPS Growth (3Y CAGR)	-0.19%	2.77%

Financial Strength

Current Ratio (MRQ)

Both Qiagen (QGEN) at 2.63 and Regeneron Pharmaceuticals (REGN) at 3.35 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 25.13
Q3: 12.13
Median: 5.52
QGEN: 2.63
Q1: 2.47
Min: 0.10

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Qiagen (QGEN) at 0.47 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.47

Max: 1.42
Q3: 0.65
QGEN: 0.47
Median: 0.15
Q1: 0.02
Min: 0.00

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
Current Ratio (MRQ)	2.63	3.35
Debt / Equity (MRQ)	0.47	0.08
Net Debt / EBITDA	1.08	-1.17

Dividends

Dividend Yield (TTM)

Both Qiagen (QGEN) at 0.71% and Regeneron Pharmaceuticals (REGN) at 0.41% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71%

QGEN: 0.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Qiagen (QGEN) at 18.21% and Regeneron Pharmaceuticals (REGN) at 8.18% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.21%

QGEN: 18.21%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
Dividend Yield (TTM)	0.71%	0.41%
Dividend Payout Ratio (TTM)	18.21%	8.18%

Valuation

P/E Ratio (TTM)

Both Qiagen (QGEN) at 27.21 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.21

Max: 85.34
Q3: 43.46
QGEN: 27.21
Median: 26.69
Q1: 13.30
Min: 0.07

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Qiagen (QGEN) at 4.91 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.91

Max: 58.18
Q3: 25.77
Median: 7.30
QGEN: 4.91
Q1: 3.01
Min: 0.01

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Qiagen (QGEN) at 2.99 and Regeneron Pharmaceuticals (REGN) at 2.71 are valued close to their industries’ norm against book — neither stands out from peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max: 13.53
Q3: 6.54
Median: 3.25
QGEN: 2.99
Q1: 1.69
Min: -5.59

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

Qiagen (QGEN) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Qiagen (QGEN) and Regeneron Pharmaceuticals (REGN)
Metric	QGEN	REGN
P/E Ratio (TTM)	27.21	19.99
P/S Ratio (TTM)	4.91	5.54
P/B Ratio (MRQ)	2.99	2.71
Free Cash Flow Yield (TTM)	3.62%	2.76%